Clearpoint Neuro (CLPT) Registration Filing summary
Event summary combining transcript, slides, and related documents.
Registration Filing summary
14 Jan, 2026Company overview and business model
Commercial-stage medical device company focused on minimally invasive neurosurgical platforms and biologics partnerships.
Core product is the ClearPoint Navigation System, used globally for MRI-guided and operating room neurosurgery procedures.
Expanded product line includes SmartFrame Array, SmartFrame OR Stereotactic System, and ClearPoint Prism Neuro Laser Therapy System.
Biologics and drug delivery partnerships support preclinical and clinical studies for direct brain therapy delivery, with over 60 customers.
Growth in biologics depends on customer relationships, clinical trial success, regulatory approvals, and therapy commercialization.
Financial performance and metrics
Classified as a "smaller reporting company" with less than $700 million in public float and under $100 million in annual revenue for the most recent fiscal year.
May continue to use scaled disclosure and reduced reporting requirements as long as thresholds are not exceeded.
Use of proceeds and capital allocation
Will not receive any proceeds from the resale of shares by selling stockholders; all proceeds go to the selling stockholders.
Latest events from Clearpoint Neuro
- Q1 2026 revenue up 43% to $12.1M, margin at 64%, but net loss widened on higher expenses.CLPT
Q1 202613 May 2026 - Pursuing $500m revenue with a global neuro platform and 60+ pharma partners in cell and gene therapy.CLPT
Investor presentation13 May 2026 - Virtual annual meeting to vote on directors, auditor, compensation, and incentive plan.CLPT
Proxy filing23 Apr 2026 - Annual meeting to vote on directors, auditor, executive pay, and expanded equity plan.CLPT
Proxy filing10 Apr 2026 - Four-pillar strategy drives neuro innovation, aiming for $200m+ revenue and global leadership.CLPT
Corporate presentation17 Mar 2026 - Record 2025 revenue and IRRAS acquisition drive double-digit growth outlook for 2026.CLPT
Q4 202517 Mar 2026 - Q2 revenue up 32% to $7.9M; guidance raised, margins expand, and global growth accelerates.CLPT
Q2 20242 Feb 2026 - Q3 revenue up 41% to $8.1M, gross margin 60%, debt repaid, 2024 guidance $30–33M.CLPT
Q3 202415 Jan 2026 - 2024 revenue up 31% to $31.4M; 2025 guidance $36–41M, fueled by FDA wins and global growth.CLPT
Q4 202423 Dec 2025